

Special Issue

Prostate Cancer Pathology and Grade

Message from the Guest Editors

This Special Issue aims to explore the evolving landscape of prostate cancer pathology, focusing on the correlation between histological grading, molecular biomarkers, and AI-driven diagnostic tools. It aligns with the journal's scope by promoting interdisciplinary research that bridges clinical pathology, computational medicine, and translational oncology. Our goal is to edit a collection of at least 10 high-quality articles, which may be published as a book if this target is met. We welcome original research, reviews, case studies, and technical reports on topics including the following:

- Gleason grading and histopathological innovations;
- Molecular profiling and genomic classifiers;
- AI applications in image analysis and predictive modeling;
- Integration of multi-omics data in clinical decision making;
- Comparative studies of traditional vs. digital pathology.

We look forward to receiving your contributions.

Guest Editors

Dr. Stefano Marletta

1. Department of Biomedical Science, Humanitas University, Milan, Italy
2. Division of Pathology, Humanitas Istituto Clinico Catanese, Catania, Italy

Dr. Giuseppe Fanelli

Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/251619

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)